Deep brain simulation (DBS) is a surgical operation used in the diagnosis of various neurological diseases like debilitating motor symptoms of Parkinson’s disease (PD), essential tremor, and dystopia. DBS therapy is mostly suggested to patients who do not make a response to medicinal drugs for five years. During this medical aid, electrodes are inserted in specific areas of the affected brain that deliver electrical impulses that command abnormal impulses. Further, this treatment is allowable by the U.S. Food and Drug Administration (FDA), for patients who cannot have epilepsy surgery, which separates or eliminates the part of the brain which causes seizures.
The study of,’ Global Deep Brain Simulation Devices Market to reach USD 1.86 billion by 2026’ These key market players are focusing on launching innovative medical devices, building growth strategies, and technological advancements to strengthen their position in the world market. Major players in the industry include Medtronic plc, Boston Scientific Corporation, Abbott Laboratories, Aleva Neurotherapeutics SA, Functional Neuromodulation Ltd., Beijing PINS Medical Co., Ltd., and NeuroPace, Inc. The market is further segmented on the premise of product, application, and end-user. By Product into Single Channel Deep Brain Stimulator and Dual Channel Deep Brain Stimulator. By Application into Pain Management, Epilepsy, Parkinson’s disease, Essential Tremor and Others. By End-Use into Hospitals, Neurology Clinics, Ambulatory Surgical Centers and Research Centers.
An increase in the widespread presence of a neurological disorder like Parkinson, surging investment for neurologic R&D and escalating demand for low invasive methods owing to the increased patient results are the few factors responsible for the high expansion of the market over the forecast amount. According to a study of the Global Burden of Disease 2015, it is estimated that the prevalence of Parkinson’s disease to be approximately 6.2 million people worldwide in 2015 and it would reach approximately 13 million people with Parkinson’s by 2040. Additionally, various Parkinson’s disease Foundations shows that approximately 60,000 Americans are treated with Parkinson’s disease each year. Which, in turn, is anticipated to accelerate the demand for deep brain stimulation devices across the globe.
The geographical analysis of global Deep Brain Stimulation Devices Market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is anticipated to emerge dominant during the forecast amount. This is attributable to the increasing developments in the healthcare sector as a result of growing research and development activities in the industry and also due to the increasing number of patients diagnosed with Parkinson, along with the wide availability of technologically advanced deep brain stimulation devices in the region. Asia Pacific is expected to expand at the highest CAGR over the forecast period because of factors like the rising prevalence of neurodegenerative disorders together with unmet demand for effective and long-term solutions. Increasing awareness about neurological disorder treatment options and improvements in clinical development framework of emerging economies are anticipated to propel the market expansion in this region.
Additionally, Potential benefits of deep brain stimulation devices, like long-term efficacy and good management of postoperative results, are predicted to drive the deep brain stimulation systems market growth. Moreover, these advancements aid clinical researchers in investigational efficacy studies for the inclusion of deep brain stimulation devices in the treatment of other neurological disorders. These key factors are expected to increase the demand for deep brain stimulation devices throughout the forecast amount.
For More Information on the Research Report, refer to below links: –
Ankur Gupta, Head Marketing & Communications